Our clinical trial listings are grouped according to the phase
of the trial. The phases can be intepreted according to the following
In Phase I trials, researchers test a new drug or treatment
in a small group of people (20-80) for the first time to evaluate
its safety, determine a safe dosage range, and identify side effects.
In Phase II trials, the study drug or treatment is given
to a larger group of people (100-300) to see if it is effective
and to further evaluate its safety.
In Phase III trials, the study drug or treatment is given
to large groups of people (1,000-3,000) to confirm its effectiveness,
monitor side effects, compare it to commonly used treatments,
and collect information that will allow the drug or treatment
to be used safely.
In Phase IV trials, post marketing studies delineate additional
information including the drug's risks, benefits, and optimal
Our trial listings indicate what stage the trial is in, whether
it is currently recruiting patients, and whether it is applicable
to non-small cell or small cell lung cancer. For example, a trial
listing preceeded by:
would indicate that the trial is Phase I, accepting
patients, and is applicable to both non-small cell, and small
cell lung cancer.
The following listing:
would indicate that the trial is Phase III,
not currently recruiting patients, and applicable to non-small
cell lung cancer only.